Loading clinical trials...
Loading clinical trials...
Using Fractional Lasers and Tirbanibulin Ointment to Treat Keratinocyte Carcinomas
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Bruce Robinson, MD
New York, New York, United States
Start Date
May 16, 2025
Primary Completion Date
May 1, 2030
Completion Date
June 1, 2030
Last Updated
September 17, 2025
100
ESTIMATED participants
Tirbanibulin ointment 1%
DRUG
non-ablative fractional laser
DEVICE
Lead Sponsor
Bruce Robinson, MD
NCT07042295
NCT05039801
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions